Evaluation of Verapamil Efficacy in Peyronie’S Disease Comparing With Pentoxifylline

Abstract

Introduction:Peyronie’s disease described as penile curvature, fibromathosis and pain that occur most often in men aged 40 to 60 years. The main complaint that caused the patient to visit the clinic is nodules on the upper surface of the penis, causing curvature and distortion particularly during erection, but they don’t have any urinary problem. In this study, we evaluated the effect of verapamil compared to pentoxifylline in Peyronie’s disease.Method:In this study, 90 patients with signs and symptoms of Peyronie’s disease which were diagnosed and were in the age range 40 to 70 years enrolled. The patients were randomly divided into 3 groups. First group received pentoxifylline orally at a dose of 400 mg three times a day, in the second group verapamil (10 mg every other week for up to 12 sessions) was injected into the lesion and the third group received both treatments in combination.Results:In patients, who received pentoxifylline, curvature reduction was 26.7%, plaque size reduction was 30%, the recovery rate of erectile dysfunction was 46.7% and pain reduced was 73.3%. Each of these cases in patients, who used beta-blockers, was 36.7%, 33.3%, 66.7% and 76.6%. In combination therapy, curvature reduction was 36.7%, plaque size reduction was 33.3%, the recovery rate of erectile dysfunction was 86.7% and pain reduced was 80%.Conclusion:In our study there was no significant difference between two groups using verapamil or pentoxifylline, but there was a significant improvement in combination therapy group. Due to our results we propose that combination therapy can improve results and should be considered as a choice in treatment of Peyronie’s disease.

Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study

“…As other authors previously reported, we decided to use PTX to treat PD in its initial, not yet stabilized phase, 31 , 32 intrigued by the interesting properties of PTX, which has been used since 1976 and is commonly employed to treat circulatory disorders, in particular in chronic peripheral artery disease. 55 , 56…”

Do People with Disabilities Have Difficulty Finding a Family Physician?

“…Physical barriers to disabled patients, such as stairs, doorways, elevated examining tables, are the most obvious, and arguably the easiest to eliminate. Family physicians have been shown to be resourceful and adaptive in their attempts to improve access despite physical barriers Typical accommodations include seeing patients at an alternate accessible site, examining patients in their wheelchairs, rather than transferring to an examining table, making home visits, communicating by phone, email or skype [ 25 , 33 ].…”

“…Accessibility and human rights legislation in most jurisdictions is aimed at ensuring this most basic aspect of access; and yet, as Pharr [ 33 ] notes, even where practice administrators are aware of the legislation, there is no assurance that accessibility standards will be met. Osmun, Chan and Solomon [ 15 ] outline medical, legal and ethical considerations associated with providing primary care to people with disabilities.…”

“…The profession is aware of the practice of differential selection of patients, and in recent years has gone on record to state that profit maximization at the expense of patient equity is not acceptable [ 29 , 30 , 31 ]. Guidelines exist in many jurisdictions advising physicians against this practice; however, these guidelines also typically uphold the physician’s prerogative to limit his or her scope of practice, and to interview and select patients in accordance with that scope, in spite of difficulties this may cause for patients [ 32 , 33 ]. The College of Physicians and Surgeons of Ontario recognizes that differential selection has the potential to be interpreted as a violation of human rights; further they acknowledge that such practices undermine the public trust in the medical profession [ 32 ].…”

The History of Collagenase Clostridium Histolyticum

“…Similar to the aforementioned therapies, large‐scale and well‐controlled trials have been lacking despite promising results for limited patient cohort sizes in both the acute/early and chronic/mature PD populations [30–32]. Intralesional verapamil has also been used in combination with oral antioxidant therapy with objective responses in penile curvature reduction, plaque size lessening, and erectile function improvement [33,34]. Other combinations with iontophoresis and topical therapy have been reported with favorable results [35,36].…”